Infections

All Conditions

Symptoms and General Pathology

Respiratory Tract (Lung and Bronchial) Diseases

Communicable Diseases

COVID-19

Pneumonia

Pneumonia, Viral

Respiratory Tract Infections

Virus Diseases

Coronavirus Infections

Coronaviridae Infections

Nidovirales Infections

RNA Virus Infections

Lung Diseases

Respiratory Tract Diseases

All patients will be treated with 1 or more convalescent plasma units

Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included

Convalescent Plasma from COVID-19 donors

Christian Caglevic, MD

Christian Caglevic, md

Raimundo Gazitua, MD

COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related

This is a collaborative, 4 arms , non randomized clinical trial assessing the use of Convalescent Plasma from COVID-19 recovered donors to be used in oncological and non-oncological patients with current severe COVID-19 infection or in patients with risk factors of major complications secondary to COVID-19 infection

COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)

Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID)

in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma

safety of convalescent plasma from COVID 19 donors (CTCAE V5.0)

any cause of mortality during these periods

based on results from this trial comparing with official information

number of days of hospitalization in high complexity facilities after convalescent plasma use

number of days of hospitalization in intensive care unit after convalescent plasma use

number of days of mechanical ventilatory support in patients after convalescent plasma use

total number of days of mechanical ventilatory support

total number of hospitalization days in patients treated with convalescent plasma

total number of hospitalization days in patients after treatment with convalescent plasma

COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies

negativization of COVID 19 load since convalescent plasma use

negativization of COVID 19 load since hospitalization

negativization of COVID 19 load since first reported symptoms COVID-19 related

Granulocyte Macrophage Colony Stimulating Factor measurement from donor

Tumor Necrosis Factor Alfa measurement from donor

Interleukin -1 beta measurement from donor

Interferon Gamma measurement from receptor

Granulocyte Macrophage Colony Stimulating Factor measurement from receptor

Tumor Necrosis Factor Alfa measurement from receptor

Interleukin -1 beta measurement from receptor

Interleukin -10 measurement from receptor

Spots Global Cancer Trial Database for general population